<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ekf Diagnostics Holdings Plc — News on 6ix</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc</link>
<description>Latest news and press releases for Ekf Diagnostics Holdings Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ekf-diagnostics-holdings-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d57d89beedb30cb6f895af.webp</url>
<title>Ekf Diagnostics Holdings Plc</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc</link>
</image>
<item>
<title>Board Changes</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/board-changes-561</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/board-changes-561</guid>
<pubDate>Mon, 27 Apr 2026 06:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc has appointed Helen Jones FCA as its new Chief Financial Officer, effective immediately, succeeding Stephen Young who is retiring. Jones brings over 20 years of finance and operations experience in high-growth, technology-driven AIM-listed businesses, most recently holding a senior role at Surgical Science following its acquisition of Intelligent Ultrasound Group plc, where she previously served as CFO. Her background includes leading successful equity placings, dive</description>
</item>
<item>
<title>Posting of Annual Report & Notice of AGM</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/posting-of-annual-report-and-notice-of-agm-197</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/posting-of-annual-report-and-notice-of-agm-197</guid>
<pubDate>Fri, 24 Apr 2026 15:43:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc has published its Annual Report and Accounts for the year ended 31 December 2025 and the Notice of its 2026 Annual General Meeting, which will be held on 19 May 2026. The company is seeking shareholder approval for a proposed share buyback authority, allowing for the repurchase of up to 64,575,466 ordinary shares. Crucially, a Rule 9 waiver is also being sought from the Takeover Panel to exempt the "Concert Party," which collectively holds approximately 29.51% of the</description>
</item>
<item>
<title>Acquisition of assets from Beep Insights</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/acquisition-of-assets-from-beep-insights</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/acquisition-of-assets-from-beep-insights</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc has acquired the Beep Insights Technology, an iOS and Android software application that integrates sports performance wearable data with real-time glucose and lactate tracking, to enhance its Sports Performance product range, particularly the Lactate Scout Sport device. This acquisition aims to provide personalized metrics for improved sports training outcomes and will see the CEO of Beep Insights join EKF to explore AI integration within performance training.
</description>
</item>
<item>
<title>Share Buyback</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/share-buyback-19</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/share-buyback-19</guid>
<pubDate>Fri, 10 Apr 2026 08:12:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc has purchased 400,000 of its ordinary shares at a weighted average price of 24.5 pence per share, with these shares to be cancelled. Following this buyback, the company's total issued share capital will consist of 430,503,112 ordinary shares, all of which carry voting rights.
Disclaimer*</description>
</item>
<item>
<title>Full year results</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/full-year-results-142</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/full-year-results-142</guid>
<pubDate>Tue, 24 Mar 2026 07:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc reported full-year results for the year ended 31 December 2025, showing revenues of £51.6 million, a 2.8% increase from £50.2 million in 2024, with gross profit rising to £26.5 million and gross margins improving to 51%. Adjusted EBITDA grew by 9.3% to £12.4 million from £11.3 million, and profit before tax was £7.1 million, up from £6.3 million. The company generated £11.6 million in net cash from operations, and its net cash and cash equivalents stood at £15.8 mill</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/holdings-in-company-1225</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/holdings-in-company-1225</guid>
<pubDate>Thu, 19 Mar 2026 07:00:00 GMT</pubDate>
<description>Liontrust Investment Partners LLP has notified EKF Diagnostics Holdings PLC of a change in its major holding, with the total voting rights and financial instruments now standing at 10.057%, down from a previous 10.956%. This change, effective March 17, 2026, resulted from an acquisition or disposal of voting rights, leading to Liontrust holding 43,070,095 direct voting rights representing 9.979% and 336,221 indirect voting rights through securities lending, representing 0.078%. The total number </description>
</item>
<item>
<title>Notice of Results</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/notice-of-results-426</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/notice-of-results-426</guid>
<pubDate>Thu, 05 Mar 2026 07:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc will announce its full year results for the year ended 31 December 2025 on Tuesday 24 March 2026, with management hosting two presentations on the same day, one online via Investor Meet Company at 11:00 am GMT and another in-person in the City of London at 5:30 pm GMT.
Disclaimer*</description>
</item>
<item>
<title>Three-year Hematology purchasing agreement</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/three-year-hematology-purchasing-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/three-year-hematology-purchasing-agreement</guid>
<pubDate>Tue, 03 Mar 2026 07:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc has secured a significant three-year group purchasing agreement with Blood Centers of America (BCA), the largest blood supply network in the U.S., covering its DiaSpect Tm handheld hemoglobin analyzer and associated consumables, as well as an EKF Link IT license. This agreement, which follows high interest generated at a recent industry meeting, is a key milestone in EKF's strategic plan to become a leader in global Point-of-Care Hematology testing, targeting the sub</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/total-voting-rights-920</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/total-voting-rights-920</guid>
<pubDate>Mon, 02 Mar 2026 15:30:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc has announced its total voting rights, stating that the issued share capital comprises 431,963,112 ordinary shares of 1p each, with 141,000 shares held in treasury, resulting in 431,822,112 ordinary shares carrying voting rights. This figure will serve as the denominator for shareholders determining notification requirements under the FCA's Disclosure and Transparency Rules regarding their interests in the company's share capital.
Disclaimer*</description>
</item>
<item>
<title>Share Buyback Programme</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/share-buyback-programme-101</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/share-buyback-programme-101</guid>
<pubDate>Thu, 19 Feb 2026 07:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc announced a share buyback program to repurchase up to 5,000,000 ordinary shares, representing approximately 1.15% of its issued share capital, funded by existing cash resources with a maximum aggregate payment limit of £1 million. The buyback, managed by Singer Capital Markets, aims to return cash to shareholders and reduce share capital, and will run until the earlier of the completion of purchases, the 2026 AGM if further approval isn't obtained, or December 31, 20</description>
</item>
<item>
<title>Share Buyback & Completion of Buyback Programme</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/share-buyback-and-completion-of-buyback-programme</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/share-buyback-and-completion-of-buyback-programme</guid>
<pubDate>Mon, 02 Feb 2026 07:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc has successfully completed its share buyback programme, purchasing a total of 17,130,678 ordinary shares at a weighted average cost of 26.14 pence per share. The most recent transaction on January 30, 2026, involved the acquisition of 159,000 shares at an average price of 25.6875 pence, with these shares to be held in treasury. Following these purchases, the company's total voting rights stand at 431,963,112. Notably, a portion of the buyback involved 47,000 shares a</description>
</item>
<item>
<title>FY 2025 Trading Update</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/fy-2025-trading-update-4</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/fy-2025-trading-update-4</guid>
<pubDate>Tue, 27 Jan 2026 07:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc reported a strong FY 2025, with revenues increasing 3% to £51.6 million and gross margins improving to 51%, driven by growth in Point-of-Care and Life Sciences divisions. Adjusted EBITDA is projected to rise nearly 10% to £12.4 million, in line with forecasts, and cash reserves grew to £15.8 million as of December 31, 2025, with no bank borrowings. The company also continued its share buy-back program, purchasing shares at an average price of 25.13 pence.
</description>
</item>
<item>
<title>Executive Chair share purchase</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/executive-chair-share-purchase-1</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/executive-chair-share-purchase-1</guid>
<pubDate>Tue, 16 Dec 2025 07:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc announced that its Executive Chair, Julian Baines, purchased 85,000 ordinary shares at 23.0 pence per share on December 15, 2025. Following this transaction, Mr. Baines now holds 1,751,288 ordinary shares, representing approximately 0.40% of the company's issued share capital. This purchase by a key executive could be viewed positively by the market as a sign of confidence in the company's future prospects.
Disclaimer*</description>
</item>
<item>
<title>Cancellation of Treasury Shares & TVR</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/cancellation-of-treasury-shares-and-tvr-3</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/cancellation-of-treasury-shares-and-tvr-3</guid>
<pubDate>Mon, 08 Dec 2025 07:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings plc has completed the cancellation of 13,710,698 ordinary shares, acquired through its share buyback programme, effective December 2, 2025. Following this cancellation, the company's total issued share capital stands at 435,383,092 ordinary shares, with no shares held in treasury. This updated figure of 435,383,092 voting rights will serve as the denominator for shareholders calculating their notification requirements under the FCA's Disclosure and Transparency Rules.
</description>
</item>
<item>
<title>Share Buyback & Extension of Buyback Programme</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/share-buyback-and-extension-of-buyback-programme</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/share-buyback-and-extension-of-buyback-programme</guid>
<pubDate>Tue, 21 Oct 2025 14:10:00 GMT</pubDate>
<description>EKF Diagnostics Holdings PLC announced the purchase of 919,331 ordinary shares at a weighted average price of 28 pence per share, which will be held in treasury. The company also declared an extension to its share buyback program, with intentions to purchase additional ordinary shares up to £1.0 million, also to be held in treasury. Following the purchase, the company's total issued share capital will consist of 449,093,790 Ordinary Shares, of which 3,575,045 Ordinary Shares are held in treasury</description>
</item>
<item>
<title>Share Buyback (Replacement)</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/share-buyback-replacement-1</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/share-buyback-replacement-1</guid>
<pubDate>Mon, 20 Oct 2025 11:24:00 GMT</pubDate>
<description>EKF Diagnostics Holdings PLC announced an amendment to a previous share buyback announcement, correcting the weighted average price to 27.5269 pence per share. The company purchased a total of 929,169 ordinary shares at prices ranging from 27.5p to 28p on October 17, 2025. Following the purchase, the total issued share capital will consist of 449,093,790 Ordinary Shares, with 2,655,714 held in treasury, resulting in 446,438,076 Ordinary Shares carrying voting rights. As part of the buyback, EKF </description>
</item>
<item>
<title>Long Term Incentive Plan</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/long-term-incentive-plan-11</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/long-term-incentive-plan-11</guid>
<pubDate>Tue, 16 Sep 2025 06:15:00 GMT</pubDate>
<description>EKF Diagnostics Holdings PLC announced the establishment of a Long Term Incentive Plan (LTIP) on September 9, 2025, with the first award granted on September 16, 2025. The Award grants the Chief Executive Officer options over 500,000 ordinary shares priced at 1p each. The vesting of the Award is contingent on the total percentage growth of Adjusted EBITDA per share over a three-year performance period. Full vesting (100%) occurs with growth of 25% or higher, 25% vesting at 10% growth, and no ves</description>
</item>
<item>
<title>Notice of interim results</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/notice-of-interim-results-136</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/notice-of-interim-results-136</guid>
<pubDate>Wed, 10 Sep 2025 06:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings PLC will release its interim results for the six months ending June 30, 2025, on Tuesday, September 16. The company will host a live online investor presentation on the same day at 10:30 am (BST) via the Investor Meet Company platform. A recording of the presentation, along with the slides and Q&A responses, will be available on the Investor Meet Company platform afterward.
Disclaimer*</description>
</item>
<item>
<title>Hematology contracts signed worth EUR 4.65m</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/hematology-contracts-signed-worth-eur-465m</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/hematology-contracts-signed-worth-eur-465m</guid>
<pubDate>Tue, 26 Aug 2025 06:00:00 GMT</pubDate>
<description>EKF Diagnostics Holdings PLC announced the signing of three new hematology point-of-care testing contracts worth approximately €4.65 million (c. £4.03m), to be delivered over the next 12 to 24 months. These contracts, secured by EKF's distribution partners in Latin America and Africa, include a return to sales in Peru and first sales into Uganda. To meet rising demand, EKF successfully increased supply capacity going into H2 2025 and will further invest to grow Hemoglobin consumable and analyser</description>
</item>
<item>
<title>H1 2025 Trading Update</title>
<link>https://6ix.com/company/ekf-diagnostics-holdings-plc/news/h1-2025-trading-update-13</link>
<guid isPermaLink="true">https://6ix.com/company/ekf-diagnostics-holdings-plc/news/h1-2025-trading-update-13</guid>
<pubDate>Mon, 28 Jul 2025 06:00:00 GMT</pubDate>
<description>H1 2025 Trading Update.</description>
</item>
</channel>
</rss>